Pure Global

Anti-HBc (MAGLUMI® Anti-HBc ) - India CDSCO Medical Device Registration

Anti-HBc (MAGLUMI® Anti-HBc ) is a medical device registered with India's Central Drugs Standard Control Organization (CDSCO) under UID IMP/IVD/2023/000036_ce169a1c31c64cdc8d73767f91b78ba3_8fc5e6756c42c0b1f9caaf99ee0e3090. This device is marketed under the brand name CLIA. The license holder is SNIBE DIAGNOSTIC (India) Private Limited., and it is classified as Device Class Class C. The approving authority is CDSCO.

This page provides comprehensive regulatory information including complete registration details, license holder information, device classification, and related products. Pure Global AI offers free access to 71,807+ India medical device registrations, helping global MedTech companies identify partners, analyze markets, and discover business opportunities efficiently.

Free Database
Powered by Pure Global AI
CDSCO Registered
Class Class C
Anti-HBc (MAGLUMI® Anti-HBc )
UID: IMP/IVD/2023/000036_ce169a1c31c64cdc8d73767f91b78ba3_8fc5e6756c42c0b1f9caaf99ee0e3090

Brand Name

CLIA

Device Class

Class C

Approving Authority

CDSCO

Product Information

The kit is an in vitro chemiluminescence immunoassay for the qualitative determination of Anti-HBc in human serum and plasma using the MAGLUMI series Fully-auto chemiluminescence immunoassay analyzer and Biolumi series Integrated System, and the assay is used as an aid in the diagnosis of HBV infection and for screening of blood donations.

Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing